Praxis Precision Medicines (PRAX) CFO has 139 shares withheld for taxes

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. reported an insider equity transaction by its Chief Financial Officer, Kelly Timothy Edwin. On 01/07/2026, 139 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units. Following this tax-related withholding, the officer directly beneficially owned 24,524 shares of Praxis common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kelly Timothy Edwin

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	139	$292.63	$41K

Holdings After Transaction: Common Stock — 24,524 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Timothy Edwin

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		F(1)		139	D	$292.63	24,524	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Praxis Precision Medicines (PRAX) report in this Form 4?

The filing reports that Chief Financial Officer Kelly Timothy Edwin had 139 shares of Praxis common stock withheld on 01/07/2026. The shares were withheld by the issuer to cover tax withholding obligations arising from the vesting of previously reported restricted stock units.

Who is the reporting person in the Praxis Precision Medicines (PRAX) Form 4?

The reporting person is Kelly Timothy Edwin, who serves as the Chief Financial Officer of Praxis Precision Medicines, Inc., and is not listed as a director or 10% owner in this filing.

How many Praxis (PRAX) shares does the CFO own after the reported transaction?

After the tax withholding transaction, Chief Financial Officer Kelly Timothy Edwin beneficially owned 24,524 shares of Praxis Precision Medicines common stock, held in direct ownership form.

What does the transaction code "F" mean in the Praxis (PRAX) Form 4?

The transaction code "F" indicates that shares were withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of equity awards, in this case previously reported restricted stock units.

Was the Praxis (PRAX) CFO’s Form 4 transaction an open market sale?

No. The Form 4 explains that the 139 shares were withheld by the issuer to cover tax withholding obligations tied to restricted stock unit vesting, rather than being sold in an open market transaction.

What is the reported share price for the Praxis (PRAX) tax withholding transaction?

The Form 4 lists a price of $292.63 per share for the 139 Praxis common shares that were withheld to satisfy the reporting person’s tax withholding obligations.